Skip to search formSkip to main contentSkip to account menu

DQ 2511

Known as: DQ-2511 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1997
1997
We examined the implication of a nitric oxide (NO)-guanosine 3',5'-cyclic monophosphate (cGMP) cascade in the suppression of… 
1996
1996
We compared the main pharmacological effect of DQ‐2511 (3‐[[[2‐(3,4‐dimethoxyphenyl)‐ethyl]carbamoyl]methyl]amino ‐N… 
1996
1996
1. DQ-2511 is a new substituted benzamide compound that has gastric prokinetic properties. Actions of the drug on neural… 
1996
1996
A previous study revealed that DQ-2511, a new gastroprokinetic drug, induced hemolytic anemia together with increased Heinz body… 
1995
1995
The pharmacological characteristics of DQ-2511, a substituted benzamide (3-[[[2-(3,4-dimethoxyphenyl)ethyl]carbamoyl]methyl… 
1995
1995
It has been reported that 3-(([2-(3,4-dimethoxyphenyl)ethyl]carbamoyl)methyl)amino-N-methylbenz amide (DQ-2511: ecabapide… 
1993
1993
DQ-2511, a new anti-ulcer drug, was administered to beagle dogs for 4 weeks to investigate the mechanism whereby this drug… 
1992
1992
A series of acyl derivatives of 2-(3,4-dimethoxyphenyl)ethylamine (4) were synthesized and evaluated for their effectiveness to… 
1990
1990
Effects of 3-[[[2-(3,4-dimethoxyphenyl)ethyl]carbamoyl] methyl]-amino-N-methylbenzamide (DQ-2511), a newly synthesized compound…